Aduro Biotech Inc. (ADRO) Given Average Recommendation of “Hold” by Brokerages
Shares of Aduro Biotech Inc. (NASDAQ:ADRO) have been given an average rating of “Hold” by the eight ratings firms that are covering the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $19.60.
A number of equities research analysts recently weighed in on ADRO shares. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a “buy” rating in a report on Monday, October 24th. Leerink Swann set a $14.00 price target on Aduro Biotech and gave the stock a “buy” rating in a report on Monday, October 24th. Roth Capital restated a “buy” rating and issued a $20.00 price target (down previously from $22.00) on shares of Aduro Biotech in a report on Thursday, October 27th. Finally, FBR & Co restated an “outperform” rating and issued a $20.00 price target on shares of Aduro Biotech in a report on Monday, November 14th.
Aduro Biotech (NASDAQ:ADRO) traded up 0.36% during midday trading on Monday, reaching $14.00. The company’s stock had a trading volume of 123,960 shares. Aduro Biotech has a 52 week low of $7.26 and a 52 week high of $34.95. The stock’s market capitalization is $940.55 million. The firm’s 50-day moving average price is $12.44 and its 200-day moving average price is $12.87.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.09. The firm earned $3.79 million during the quarter, compared to analyst estimates of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. The business’s revenue was down 79.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 EPS. On average, analysts anticipate that Aduro Biotech will post ($1.34) earnings per share for the current year.
In other Aduro Biotech news, Director Ross Haghighat sold 7,088 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $15.50, for a total transaction of $109,864.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Stephen T. Isaacs sold 27,273 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $12.67, for a total value of $345,548.91. Following the transaction, the chief executive officer now directly owns 129,473 shares in the company, valued at approximately $1,640,422.91. The disclosure for this sale can be found here. 6.50% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. American Century Companies Inc. acquired a new position in shares of Aduro Biotech during the second quarter worth $1,265,000. Emerald Acquisition Ltd. purchased a new stake in Aduro Biotech during the second quarter worth approximately $454,000. Alps Advisors Inc. increased its stake in Aduro Biotech by 27.7% in the second quarter. Alps Advisors Inc. now owns 90,766 shares of the company’s stock worth $1,027,000 after buying an additional 19,663 shares during the last quarter. BVF Inc. IL purchased a new stake in Aduro Biotech during the second quarter worth approximately $5,809,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Aduro Biotech during the second quarter worth approximately $314,000. 28.50% of the stock is currently owned by institutional investors.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.